Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling
MEK抑制剂
癌症研究
受体酪氨酸激酶
激酶
医学
生物
MAPK/ERK通路
生物化学
作者
Johanna C. Bendell,Susanna V. Ulahannan,M. Koczywas,Julie R. Brahmer,Anna Capasso,S. Gail Eckhardt,Michael S. Gordon,Caroline E. McCoach,Misako Nagasaka,Kimmie Ng,Jorge H. Limón-Pacheco,Jonathan W. Riess,Alexander I. Spira,Conor Steuer,Richa Dua,Suramanyam Chittivelu,Serena Masciari,Z. Wang,X. Wang,S.‐H.I. Ou
PDF的下载单位、IP信息已删除
(2025-6-4)
GingerF
Nole
Kao
OK
LB
MchemG
Samuel
Criminology34
cnspower
笨笨的元绿
xuxi
sci_fp
youth
lizishu
阮小粒
寻梦
Rita
dynamoo
Copyright
无极微光
皖公网安备34019202002308
